Document is current
Any future updates will be listed below
-
Authors
Willems, Laurent Maximilian https://orcid.org/0000-0001-8226-1674
Beuchat, Isabelle
Fisch, Urs
Sutter, Raoul
Kellinghaus, Christoph
Strzelczyk, Adam
-
Funding
Funding for this research was provided by:
Johann Wolfgang Goethe-Universität, Frankfurt am Main
- License Information
-
More Information
Article History
Received: 5 September 2025
Accepted: 30 September 2025
First Online: 24 October 2025
Declarations
:
: Not applicable.
: Not applicable.
: Laurent M. Willems received speaker’s fees from StreamedUp GmbH outside the submitted work. Isabelle Beuchat reported no competing interests. Urs Fisch reported no competing interests. Raoul Sutter received research grants from the Swiss National Foundation (No 320030_169379), the Research Fund of the University Basel, the ScientificSociety Basel, and the Gottfried Julia Bangerter-Rhyner Foundation. Hereceived personal grants from UCB-pharma and holds stocks from Novartis, Roche, Alcon, and Johnson & Johnson. Christoph Kellinghaus has received speaker’s honoraria from Angelini Pharma,Eisai, Jazz Pharmaceuticals, UCB, LivaNova. He has served on advisory boardsfor Angelini Pharma, Eisai and Marinus Pharma. Adam Strzelczyk reports personal fees and grants from Angelini Pharma, Biocodex, Desitin Arzneimittel, Eisai, Jazz Pharmaceuticals, Longboard, Neuraxpharm, Stoke Therapeutics, Takeda, UCB, and UNEEG. Adam Strzelczyk reports that he is part of the editorial board of Neurological Research and Practice and editor-in-chief of Clinical Epileptology .
